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Abstract
Background: Cell survival depends on the balance between protective and apoptotic signals. When the balance of signals
tips towards apoptosis, cells undergo programmed cell death. This balance has profound implications in diseases including
cancer. Oncogenes and tumor suppressors are mutated to promote cell survival during tumor development, and many
chemotherapeutic drugs kill tumor cells by stimulating apoptosis. BAD is a pro-apoptotic member of the Bcl-2 family of
proteins, which can be phosphorylated on numerous sites to modulate binding to Bcl-2 and 14-3-3 proteins and inhibit its
pro-apoptotic activities. One of the critical phosphorylation sites is the serine 112 (S112), which can be phosphorylated by
several kinases including Pak1.
Methodology/Principal Findings: We mapped the Pak phosphorylation sites by making serine to alanine mutations in BAD
and testing them as substrates in in vitro kinase assays. We found that the primary phosphorylation site is not S112 but
serine 111 (S111), a site that is sometimes found phosphorylated in vivo. In transfection assays of HEK293T cells, we showed
that Pak1 required Raf-1 to stimulate phosphorylation on S112. Mutating either S111 or S112 to alanine enhanced binding
to Bcl-2, but the double mutant S111/112A bound better to Bcl-2. Moreover, BAD phosphorylation at S111 was observed in
several other cell lines, and treating one of them with the Pak1 inhibitor 2,29-Dihydroxy-1,19-dinaphthyldisulfide (IPA-3)
reduced phosphorylation primarily at S112 and to a smaller extent at S111, while Raf inhibitors only reduced
phosphorylation at S112.
Conclusion/Significance: Together, these findings demonstrate that Pak1 phosphorylates BAD directly at S111, but
phosphorylated S112 through Raf-1. These two sites of BAD serve as redundant regulatory sites for Bcl-2 binding.
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Introduction
Many apoptotic stimuli disrupt the integrity of the mitochon-
dria, causing them to release pro-apoptotic contents such as
cytochrome c and apoptosis inducing factor (AIF) [1]. One of the
triggers of mitochondrial disruption is the translocation of BAD, a
pro-apoptotic member of the Bcl-2 family. BAD activity is
regulated by phosphorylation, which reduces its activity [2,3].
Akt phosphorylates serine 136 (S136); PKA phosphorylates serines
112 (S112) and 155; p90RSK also phosphorylates S112; JNK
phosphorylates serine 128 (S128) and threonine 201; Cdc2
phosphorylates S128 [4–11].
Raf-1 promotes cell survival through multiple mechanisms.
Whereas plasma membrane targeting of Raf-1 activates the classical
MEK.ERK (MAPK) cascade but does not protect cells, mitochon-
drial targeting of Raf-1 protects cells [12]. There are conflicting
studies on the role of Raf-1 in BAD phosphorylation [12–14],
however, the most recent studies using Raf inhibitors suggest that
Raf-1 and other Raf isoforms phosphorylate BAD on S112 [15,16].
Paks (p21-activated kinases), which are the effectors for the
small GTPases Rac and Cdc42, have a major role in signaling
pathways to promote cell migration, cell proliferation transforma-
tion and survival [17–22]. Pak1 and other isoforms stimulate
phosphorylation at S112 and S136 of BAD in vitro and in vivo.A
survey of 98 signaling antibodies found that phosphorylation at
S112 and S136 were pharmacodynamic markers for measuring
the effectiveness of Pak inhibitors in vivo [23–28]. More recent
studies have found that Pak stimulation of S112 phosphorylation
may be indirect, proceeding through Raf-1 [15,16]. Additionally,
Pak1 and Pak5 stimulate Raf-1 complexes with Bcl-2 and
mitochondrial translocation of Raf-1 [15,29,30].
Here through in vitro mutational analysis, we showed that
neither S136 nor S112 of BAD was a significant site of Pak1
phosphorylation. Instead, the vast majority of phosphorylation by
Pak1 occurred at S111, a site recently identified in cells. Using
transfection assays in HEK293T cells, we also confirmed that Pak1
can phosphorylate S112 through Raf-1. In addition, we found that
S111 phosphorylation may precede S112 phosphorylation to
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e27637facilitate S112 phosphorylation. Bad phosphorylation at S111 was
observed in several other cell lines, and inhibition of Pak1 with
inhibitor 2,29-Dihydroxy-1,19-dinaphthyldisulfide (IPA-3) reduced
phosphorylation at S111 and S112.
Materials and Methods
Materials
Dulbecco’s modified Eagle’s medium (DMEM) and fetal bovine
serum were from Invitrogen (Carlsbad, CA). FuGENE 6
transfection reagent, complete protease inhibitor cocktail tablets
were from Roche (Indianapolis, IN). Rabbit polyclonal antibodies
against BAD, phospho-Ser112, phospho-Ser136, ERK, phospho-
ERK, phospho-c-Raf (Raf-1) (Ser338) were from Cell Signaling
Technology (Beverly, MA). Antibodies against Bcl-2 (N-19) and
14-3-3 (C-16) were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA). 5-Iodo-3-[(3,5-dibromo-4-hydroxyphenyl)-
methylene]-2-indolinone (GW5074), rapamycin, and 2,29-Dihy-
droxy-1,19-dinaphthyldisulfide (IPA-3) were from CalBiochem (La
Jolia, CA). PD098059 and H89 were purchased from Sigma (Saint
Louis, MO). Glutathione SepharoseTM 4B was purchased from
Amersham Pharmacia Biotech (Uppsala, Sweden).
Plasmids
Plasmids expressing a Myc-tagged wild-type (WT), a kinase-
dead (KD or K299R) and a kinase-activated (T423E) version of
Pak1 cloned into the pCMV6 vector have been described
elsewhere [31]. The plasmids used to generate GST-BAD
(aa104-141) fusion proteins were provided by the late Dr. Stanley
Korsmeyer. Fragment GST-BAD wild-type (WT), GST-BAD
S111A, GST-BAD S112A, GST-BAD S136A, GST-BAD S112/
111A, GST-BAD S111/136A, GST-BAD S112/136A, GST-
BAD S112/136/108A, GST-BAD S112/136/134A, GST-BAD
S112/136/111A, and GST-BAD S112/136/128A were all cloned
into the pGEX-4T-1. pBAC-his-hPak1, which expresses a human
Pak1 cloned into a baculovirus expression system, was provided by
Dr. Jonathan Chernoff. pEBG-BAD encoding GST tagged with
the full length BAD was purchased from Cell Signaling. This
plasmid was used to create GST-BAD S111A, GST-BAD S112A,
GST-BAD S136A, GST-BAD S111/112A, GST-BAD S111/
136A, GST-BAD S112/136A, and GST-BAD S111/112/136A
by mutating the specific amino acid(s) within the full length BAD.
Plasmids expressing mutant BAD (full length or aa104–141) were
constructed using site-directed mutagenesis (Stratagene).
Antibody Production
The S111-phosphorylated peptide, ETRSRH[pS]SYPAGTE,
corresponding to amino acid residues 105 to 118 of mouse BAD,
was synthesized (ResGen, Invitrogen Corporation), conjugated to
KLH and injected into rabbits for antibody production. To affinity
purify the antibody, the peptide was cross-linked to NHS (N-
hydroxysuccinimide)-activated Sepharose 4 Fast Flow beads
(Amersham-Pharmacia Biotech) as instructed by the manufacturer
and the beads were used to purify the anti-phospho-BAD (S111)
serum.
Cell Culture and Transfection
HEK293T, and a malignant peripheral nerve sheath tumor
(MPNST) cell line ST88-14, were grown at 37uCi n5 %C O 2 and
cultured in DMEM containing 10% fetal bovine serum, penicillin
(100 units/ml), and streptomycin (100 mg/ml). Cells were
transfected using FuGENE 6 for 24 hr, and then starved overnight
before harvesting. A human lung cancer cell line H358, and
MPNST cell lines, 90-8 and STS26, were cultured in RPMI
containing 10% fetal bovine serum, penicillin (100 units/ml), and
streptomycin (100 mg/ml).
Immunoblot and Immunoprecipitation
Cells were transfected with appropriate vectors. Cell extracts were
prepared using lysis buffer (50 mM HEPES pH 7.5, 0.15 N NaCl,
1.0% NP-40, 1 mM EDTA, 1 mM EGTA, 1 mM glycerophosphate,
0.5 mM vanadate and 10% glycerol) supplemented with 1 mM
phenylmethlsulfonyl fluoride and the recommended concentration of
Complete protease inhibitors (Roche). Protein concentration was
assessed using the Bio-Rad Dc Protein Assay Kit and equal amounts of
proteins were separated by SDS-PAGE, transferred to polyvinylidene
difluoride membranes (Immobilion P; Millipore Corp). Blots were
blocked for 1 hr in TBS-T (Tris-Buffered Saline with Tween-20) buffer
supplemented with 5% nonfat milk, and incubated with primary
antibodies overnight at 4uC. After washing, blots were incubated with
secondary antibodies, and then detected using the enhanced
chemiluminescence detection system (Amershan Pharmacia Biotech).
The immunoprecipitation assay was carried out as following: whole cell
lysates containing the same amount of total protein were incubated
with glutathione beads for 4 hr at 4uC. Beads were collected by
centrifugation and washed twice with the lysis buffer and once with
1xPBS. Proteins were eluted by boiling in 1xSDS sample buffer, and
subjected to immunoblotting, and then probed with antibodies against
p-Ser112 BAD, p-Ser111 BAD, Bcl-2 or 14-3-3.
Kinase Assays
Protein kinase assays were conducted by incubating a mixture of
proteins with the indicated substrates in 1X kinase buffer (10 mM
MgCl2, 40 mM Hepes, pH 7.4) supplemented with 5 mM ATP or
where indicated 5 mCi of c-[
32P] ATP for 30 min at 30uCi na
reaction volume of 25 mL. The reaction was terminated with
1XSDS sample buffer, followed by SDS-PAGE, autoradiography
or Western blotting.
For peptide kinase assays, peptides were dissolved in Tris/
EDTA buffer to make a stock concentration of 20 mg/mL. The
Ninhydrin test was run with 2 mL of each sample spotted on a
Flexible Thin layer Chromatography (TLC) plate to ensure the
equal loading of the peptides. The peptides were incubated with
Pak and Cdc42
L61 with or without Raf-1 in 1X kinase buffer
(10 mM MgCl2, 40 mM Hepes, pH 7.4) supplemented with
20 mM ATP and 1 mCi of c-[
32P] ATP for 30 min at 30uCi na
reaction volume of 28 mL. The reaction was terminated with 1X
Tricine SDS sample buffer (Invitrogen), run on a an SDS-PAGE
tricine gel (Invitrogen) and analyzed by autoradiography.
For autoradiography, the phosphorylation gel was exposed to a
phosphor screen and the phosphorylated BAD bands were
quantified using ImageQuant V1.2 software. The ‘‘Relative
Phosphorylation’’ was calculated based on the level of phosphor-
ylation in GST alone for Figure 1E or lane 10 for supplemental
figure 2B, which was set to a value of ‘‘1’’. Statistical analysis was
performed using student t-test for significance.
Phosphoamino Acid Analysis
After phosphorylation and electrophoresis, the phosphorylated BAD
protein band was cut out from the gel, ground up and eluted with
50 mM NH4HCO3,0 . 1 %S D Sa n d0 . 5 %b-mercaptoethanol twice in
a combined volume of 1.2 mL. 20 mg of carrier protein (RNase A) and
TCA (final concentration 20%) were added. The mixture was kept on
ice for 1 hr and then spun down at 10,000 rpm for 10 min at 4uC.
After washing with 95% ethanol and dry in air, the pellet was
hydrolyzed in 50 mL 6 N HCl for 1 hr at 110uC, lyophilized and
dissolved in 6 mL of pH 1.9 buffer (2.2% formic acid, 7.8% [V/V]
glacial acetic acid) containing 60 mg/ml unlabeled phospho-amino
Pak Signaling to BAD
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GA). The TLC plate was run in a Multiphor 2-D apparatus
(Amersham Pharmacia Biotech). The first dimension was run at
1.5 kV in pH 1.9 buffer for 20 min. After air-drying for 30–60 min,
the TLC plate was turned 90u counter-clockwise and run at 1.4 kV in
pH 3.5 buffer (0.5% glacial acetic acid, 0.05% of pyridine, V/V) for
16 min. After drying, the plate was sprayed with 0.25% (V/V)
ninhydrin in acetone and then incubated at 65uC for 15 min to
visualize the unlabeled phosphoamino acid markers which appear as
purple spots identifying to the positions of p-Ser, p-Thr and p-Tyr. The
plate was then exposed to X-ray film to identify the radiolabeled amino
acids.
Results
Schurmann et. al. demonstrated that Pak1 phosphorylated BAD
on S112 and S136 but suggested that other sites might also be
phosphorylated [24]. Since recent data suggested that Pak1
phosphorylated BAD indirectly through Raf-1 [15], we decided
to re-examine if Pak1 could phosphorylate BAD directly. Kinase
assays were performed using recombinant GST-BAD (aa 104-141)
as a substrate for Pak1.
32P labeled ATP was readily incorporated
into BAD when Pak1 was activated by Cdc42
L61 (Figure 1A, lanes
1) but only a small amount of
32P-ATP was incorporated into BAD
without Cdc42
L61 (Figure 1A, lanes 6). To map the binding site,
we mutated the two reported Pak1 phosphorylation sites, serines
112 and 136 to alanines. Mutants of either site and the S112/136A
double mutant of BAD were all phosphorylated to a comparable
extent (Figure 1A, lanes 2–4). Next, using 2D electrophoresis, we
identified the phosphorylated amino acid as serine (Figure 1B); the
serines within amino acids 104–141 are located at 108, 111, 128
and 134. To identify the serine residues that could be
phosphorylated by Pak1, we constructed additional mutations in
the S112/136A protein, and then purified and tested these GST
fusion proteins in kinase assays (Figure 1C). Mutations in 108, 128
or 134 in combination with S112/136A did not reduce
Figure 1. Pak1 phosphorylates BAD (aa 104–141) primarily on S111 instead of S112/136. (A) Pak1 phosphorylates S112/136A double
mutant of BAD. 4 mg of each GST fusion protein of fragment BAD wild type (WT aa 104–141) or mutant BAD (aa 104–141) with the mutation of serine-
to-alanine at 112, 136 or both sites was used as substrate for in vitro kinase assay with Pak1 in the present or absence of Cdc42
L61, which was used to
activate Pak1. Kinase assays were carried out using c-[
32P] ATP for 30 min at 30uC as described in Materials and Methods. One quarter of each
reaction was separated by 10% SDS-PAGE, and phosphorylated proteins were detected by autoradiography. The position of phosphorylated Pak1,
Cdc42
L61, and BAD WT and mutants were determined according to their sizes as shown in the Figure S1C. (B) Phosphoamino acid analysis of
phosphorylated GST-BAD (aa 104–141). GST-WT BAD (aa 104-141) was phosphorylated by Pak1, and the proteins were run through SDS-PAGE. The
phosphorylated BAD was isolated and subjected to acid hydrolysis and analyzed on a TLC plate as described in Materials and Methods. P-S, P-T and P-
Y represent phosphor-serine, phosphor-threonine and phosphor-tyrosine, respectively. Pi indicates orthophosphate. (C–E) Mutation at S111
abolished BAD phosphorylation by Pak1. Kinase assay was carried out as in Figure 1A, except that substrates were the indicated GST-BAD mutants (aa
104-141). Panel E shows phosphorimager quantification of the bands in panel D (n=3).
doi:10.1371/journal.pone.0027637.g001
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136A abolished almost all phosphorylation on BAD (Figure 1C,
lanes 2–6). Additional constructs that mutated S111 alone or in
combination with S112/136A confirmed that only mutation in
S111 significantly affected Pak1 phosphorylation of BAD
(Figures 1D and 1E). Similarly, an in vitro kinase assay using
BAD peptides (aa 105–118) showed that only mutation of S111
significantly reduced Pak1 and Rac
L61 phosphorylation of BAD in
this region (Figure S1D). The Coomassie brilliant blue staining
showed equal loadings of proteins (Figures S1A and B). The
position of phosphorylated Pak1, Cdc42
L61, and BAD WT and
mutants were determined according to their sizes as shown in the
Figure S1C.
Since S111 has not been reported as a Pak1 phosphorylation
site, we examined if this site can be phosphorylated in cells. First,
we designed and raised a phospho-specific antibody against S111
and characterized this antibody using in vitro kinase assays
(Figure 2A). To do this, purified peptides (aa 104–141) of GST-
wild type BAD, GST-BAD S111A, GST-BAD S112A, and GST-
BAD S112/136A were incubated with or without Pak1 and ATP.
The antibody against phospho-S111 recognized phosphorylated
GST-wild type BAD, GST-BAD S112A, and GST-BAD S112/
136A but not GST-BAD S111A (Figure 2A), indicating this
antibody is specific in detecting phospho-S111 of BAD. As a
control, we also tested a commercial antibody against phospho-
S112 of BAD, which recognized S112 phosphorylated GST-wild
type BAD and GST-BAD S111A but not the BAD peptides with
mutated S112 (Figure 2A). When
32P-labeled ATP was used as a
substrate, only the S111A mutant was a poor substrate as expected
from the experiments in figure 1 (Figure 2A, upper panel lane 2).
Coomassie brilliant blue staining of the purified proteins are
shown in Figure S1C. Next, we determined whether Pak1
phosphorylates BAD at S111 in cells. In HEK293T cells, co-
transfection of Pak1 with activated Cdc42 (Cdc42
L61, Figure 2B
lane 2), activated Rac (Rac
L61, Figure 2C lane 7), or an activated
form of Pak1, Pak1T423E (Figure 2C lane 3), all stimulated BAD
S111 phosphorylation to the same extent. No signal for BAD S111
phosphorylation was observed with a kinase dead Pak1 (KD or
K299R, Figure 2C lane 2). Mutation of serine 111 to alanine
(S111A) prevented Pak1 phosphorylation of S111 (Figure 2B lane
3, and Figure 2C lane 4 and 8). In cells transfected with
Pak1T423E alone, the BAD phospho-S111 antibody was able to
detect the endogenous phosphorylation of BAD at S111
(Figure 2D, lane2). These experiments demonstrated that Pak1
phosphorylated BAD at a unique site-S111 while we calculated
from figure 1 that only 9.8% of the phosphate was directly
incorporated into other serine sites, primarily at S112 (Figure 1D
and E, and Figure 2A).
Expression of Pak1T423E, but not kinase dead Pak1 (KD),
stimulates phosphorylationof BADat S112 (Figure 3A lane 2 and 3)
[23–26]. However, as shown in figure 1, Pak1 phosphorylation at
S112 is likely to be indirect since only a small fraction of phosphate
is incorporated into BAD at serine 112. Since S112 of BAD was
such a poor phosphate acceptor for Pak1, we hypothesized that
other protein kinases downstream of Pak1 phosphorylate BAD at
S112. Cells were co-transfected with pEBG-WT BAD (full length)
and empty vector, KD Pak1 or Pak1T423E, and then treated with
the Raf-1 inhibitor GW5074 (5-Iodo-3-[(3,5-dibromo-4-hydroxy-
phenyl)methylene]-2-indolinone), a MEK inhibitor (PD098059), a
p70S6K inhibitor (rapamycin), or a PKA inhibitor (H89). Pak1
stimulation of S112 phosphorylation was not inhibited by
PD098059, rapamycin, or H89 (Figure 3A lane 5–7). However,
the Raf-1 inhibitor GW5074 reduced phosphorylation of BAD at
S112 to the control levels (Figure 3, lane 4). This confirms earlier
Figure 2. Phosphorylation of BAD at S111 by Pak1 in 293T cells. (A) Characterization of S111 and S112 antibodies used in this study. Purified
GST-WT BAD (aa 104-141) and BAD (aa 104-141) mutants as indicated in the figure were incubated with or without Pak1 and phosphorylated with c-
[
32P] ATP for 30 min at 30uC (upper panel) and subjected to autoradiography, or phosphorylated with unlabeled ATP (lower two panels) and probed
with the S111 and S112 antibodies. (B and C) 293T cells were transfected with the indicated plasmids along with a BAD WT or S111A mutant plasmid.
Pak1T423E, CDC42
L61 and Rac
L61 are activated mutants of Pak, Cdc42 and Rac respectively. Pak1 KD is a kinase dead Pak1 mutant. Equal amounts of
extracts were incubated with glutathione beads in a GST pulldown experiment. Samples were separated by 10% SDS-PAGE and then blotted with
anti-phospho-S111 BAD antibody to assess BAD phosphorylation. Total GST-BAD and Pak1 are shown in the lower panels. (D) Endogenous BAD was
immunoprecipitated with an anti-BAD antibody and blotted with S111 phospho-specific antibody. Total BAD is shown below the blot.
doi:10.1371/journal.pone.0027637.g002
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suggesting that Raf-1 acts downstream of Pak1 to phosphorylate
S112 of BAD [15]. We also assessed the phosphorylation of ERK, a
downstream target of the Raf-1 cascade. Activated Pak1 did not
obviously stimulate ERK phosphorylation (Figure 3A lane 3).
Phosphorylation of ERK was slightly induced by the GW5074 but
reduced by PD098059 (Figure 3A lane 4 and 5). Importantly, the
Raf-1 inhibitor prevented Pak1-dependent phosphorylation of S112
but not phosphorylation at S111 (Figure 3A lane 4). Similar effects
byRaf-1onphosphorylationofS111and S112wereobserved when
dominantnegativemutantsofRaf-1wereusedtoinhibitRaf-1(data
not shown). To exclude the possibility that the Raf-1 inhibitor
interfered with the PKA pathway, we tested the effect of the Raf-1
inhibitor on PKA-induced S112 phosphorylation. 293T cells were
transfected with pEBG-WT BAD for 24 hr, starved for 16 hr and
pretreatedwithvehicle(DMSO),thePKAinhibitorH89orthe Raf-
1 inhibitor GW5074 for 30 min and then stimulated with forskolin
to activateadenylyl cyclase. H89inhibitedforskolin stimulated S112
phosphorylation,asexpected,buttheRaf-1inhibitorhadlittleeffect
(Figure 3B). An in vitro assay also showed that a mutation at S111
does not influence PKA phosphorylation of BAD at S112 (Figure
S2A). These data demonstrate that, unlike the case with Pak1, PKA
does not stimulate S112 phosphorylation through Raf-1 and most
likely phosphorylates BAD directly at S112.
To determine if preventing phosphorylation at S111 would
influence S112 phosphorylation, we tested if a mutation of S111
would affect phosphorylation at S112. Again, 293T cells were co-
transfected with expression vectors encoding full length (FL) BAD
(WT, S111A, or S112A) and Pak1 (KD or T423E). We found that
mutating S111 to alanine in full length BAD reduced Pak1
stimulated phosphorylation at S112 (Figure 4A lane 4). However,
there was no effect on forskolin stimulated (PKA dependent)
phosphorylation of S112 (Figure 4B lane 7). Thus Pak1
phosphorylation of S111 enhances S112 phosphorylation by
Raf-1. Using BAD peptides (aa 105–118), we found that activated
Raf-1 enhanced Pak1 phosphorylation of BAD (Figure S2B Lane 1
and 2). Activated Raf-1 alone, however, did not phosphorylate
phosphorylated S111 (pS111) or S111A (data not shown).
Moreover, activated Pak1 alone did not phosphorylate phosphor-
ylated S111 (pS111) or S111A but addition of activated Raf-1 led
to a weak phosphorylation of pS111 and S111A (Figure S2B Lane
3–6). Incubating Pak1 with or without Raf-1 failed to phosphor-
ylate pS112 or S111/112A (Figure S2B Lane 7–10). These data
indicate that modification of S111 in vitro may affect the efficient
S112 phosphorylation by Raf-1 and Pak1. Furthermore, these data
showed that pS112 reduces phosphorylation of S111 by Raf-1 or
Pak1. Together, these studies demonstrate that Pak1 phosphory-
lates BAD directly on S111 in vivo and indirectly on S112 through
Raf-1.
Phosphorylation of BAD at S112 and S136 decreases BAD/Bcl-
2 complex formation and increases BAD/14-3-3 binding, which
results in increased cell survival [2]. To determine if phosphor-
ylation of BAD at S111 affects complex formation, GST pull down
assays were performed with extracts from cells transfected with
pEBG-WT BAD (full length) or different mutants as indicated in
figure 5. Mutation of S111, S112, S136, or combinations of double
mutations caused a slight increase of Bcl-2/BAD binding
(Figure 5A and B). A triple mutation of the S111, S112 and
S136 sites led to the most Bcl-2/BAD complex formation
(Figure 5A lane 9 and B). We also tested 14-3-3 binding to BAD
and found that binding was dramatically decreased in mutants
with S136A mutations (Figure 5A and C), indicating that S136 is
the most important phosphorylation site for the BAD/14-3-3
complex formation as previously observed [32,33]. The enhanced
Bcl-2 binding by the triple mutant is likely the result of the release
of BAD from 14-3-3 sequestering in addition to the enhanced Bcl-
2 association.
To address if S111 of BAD is phosphorylated in other cell lines
besides 293T cells, we probed a panel of malignant peripheral
nerve sheath tumor (MPNST) cells and one lung cancer cell line
(H358) (Figure 6). The MPNST cell lines included ST88-14,
STS26, and 90-8 as well as a rat Schwannoma RT-4. We found
that Bad was phosphorylated on S111 in all of the cell lines except
RT-4, which expressed very low levels of BAD (Figure 6A, and B
lane 1; data not shown for RT-4 cells). We chose to use ST88-14
cells to examine the effects of Pak1 inhibition on BAD
phosphorylation since Pak regulates ERK in them [34]. Upon
treatment with 20 mM IPA-3, a Pak1, Pak2 and Pak3 inhibitor
[35], ST88-14 cells underwent apoptosis (data not shown). When
we treated ST88-14 with various kinase inhibitors (Figure 6B lane
3–6), we found that the Pak inhibition reduced phosphorylation of
Bad at S111 and S112. The Raf inhibitors only reduced
Figure 3. Pak1 stimulates phosphorylation of Ser112 on BAD
via Raf-1. (A) Effects of kinase inhibitors on BAD S112 phosphorylation.
293T cells were co-transfected with expression vectors encoding full
length (FL) WT BAD and Pak1 (KD or T423E). 24 hr after transfection,
cells were starved for 16 hr and treated with GW5074 (5 mM), PD098059
(20 mM), Rapamycin (5 mM) or H89 (5 mM) for 2.5 hr as indicated. Equal
amounts of proteins were used for Western blot to assess BAD
phosphorylation at S112 or S111. The cell lysates were also subjected to
immunoblotting with anti-BAD, anti-Myc, anti-phospho-ERK and anti-
ERK antibodies. (B) Effects of inhibitors on forskolin stimulated
activation of BAD phosphorylation. 293T cells were transfected with
full length (FL) WT BAD for 24 hr, starved for 16 hr and treated with
vehicle (DMSO), GW5074 (5 mM), or H89 (5 mM) for 2.5 hr prior to
forskolin (50 mM) treatment. Equal amounts of proteins were used for
Western blot to assess BAD phosphorylation at S112. The cell lysates
were also subjected to immunoblotting with anti-BAD.
doi:10.1371/journal.pone.0027637.g003
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any effect on either site, while H89 had a partial effect on S112,
but not S111. IPA-3 also reduced phosphorylation of Raf-1 at
S338, confirming that Raf-1 is a downstream target of Pak1. We
noted that exposure to IPA-3 reduced the overall levels of BAD,
which appears to account for most of the effects on S111
phosphorylation, but not the much stronger loss of phosphoryla-
tion seen at S112. The reduction of BAD upon treatment with
IPA-3 was more pronounced upon longer exposure to IPA-3
suggesting that Pak1 may also affect the stability of BAD (data not
shown).
Discussion
There are several reports of Pak1 stimulating BAD phosphor-
ylation at both S136 and S112 [15,16,23,24]. While most studies
relied on cell based assays, some documented the phosphorylation
in vitro, usually using phosphospecific antibodies [16,24,36]. We
showed here, with radioisotope, a more quantitative assay system,
that there was still a substantial phosphorylation of BAD with the
S112 and S136 double mutant. This was because the phosphor-
ylation of BAD occurs primarily on amino acid S111. Studies with
peptides have found that the preferred site of phosphorylation for
Pak1 are peptides with basic amino acids R and K at positions -2
and -3 from the phosphorylated serine and a hydrophobic residue
such as tyrosine at the +2 position. The sequence of BAD at the
region phosphorylated by Pak1 is ETRSRHSSYPAGTEE (SS are
serines 111 and 112, respectively). With R at position -2 and Y at
position +2, S111 fits well with the preferred motif although it
lacks a basic residue at -3. S112, however, has only a single
preferred component of the preferred motif, R at position -3. In
comparison to other Pak1 substrates, S111 is very similar to two
other widely documented sequences that Pak1 phosphorylates,
S338 of Raf-1, RPRGQRDSSYYWEIE and S297 of MEK,
Figure 4. Mutations on BAD S111 reduces Pak1 phosphoryla-
tion of BAD at S112. (A) 293T cells were co-transfected with
expression vectors encoding full length (FL) BAD (WT, S111A, or S112A)
and Pak1 (KD or T423E). Equal amounts of proteins were used for
Western blotting to assess BAD phosphorylation at S112. The cell
lysates were also subjected to immunoblotting with anti-BAD and anti-
Pak1 antibodies. (B) 293T cells were transfected with expression vectors
encoding full length (FL) BAD (WT, S111A, or S112A). Equal amounts of
proteins were used for Western blot to assess BAD phosphorylation at
S112. The cell lysates were also subjected to immunoblotting with anti-
Pak1 antibodies.
doi:10.1371/journal.pone.0027637.g004
Figure 5. Bcl2 and 14-3-3 binding to BAD and model. (A) Effects
of S111, S112 and S136 mutation(s) on BAD/Bcl-2 and BAD/14-3-3
complex formation. 293T cells were transfected with the full length (FL)
BAD WT or mutant plasmids as indicated in the figure. Equal amounts
of extracts were incubated with glutathione beads in a GST pulldown
experiment. Samples were separated by 10% SDS-PAGE and then
blotted with anti-Bcl-2 or anti 14-3-3 antibodies. Total Bcl-2 and 14-3-3
were also determined by Western blotting. (B and C) Protein levels were
evaluated through densitometry and two different blots for were
quantified. The ratio of immunoprecipitated and blotted Bcl-2 to total
Bcl-2, and immunoprecipitated and blotted 14-3-3 to total 14-3-3 were
plotted as B and C.
doi:10.1371/journal.pone.0027637.g005
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basic amino acid, phosphorylation at the first of two serines (Raf is
additionally phosphorylated, but to a lesser extent, at the second
serine), and a tyrosine at the +2 position. We note, however, that
Pak1 substrates are difficult to predict from sequence comparisons.
For example, we did not find BAD, Raf-1 or MEK listed among
1433 possible targets identified in a Scansite search of the Swiss
protein database [37] using a sequence matrix developed by
Peterson’s lab [38] (data not shown).
While there are numerous reports documenting phosphoryla-
tion at S112 in vivo and in vitro, S111 has only recently been found
to be phosphorylated. However, both reports were large scale
proteomics studies of phospho-proteins [39] and the responsible
kinases were not identified. Here, for the first time, we document
Pak1 as a kinase that phosphorylates BAD at S111 although the
experiments with the Pak inhibitor suggest that other kinases also
phosphorylate this site. We propose that while Pak1 phosphory-
lates BAD at serine 111, most of Pak1 protective effects are
through Raf-1 mediated phosphorylation of BAD at serine 112
(Figure 6C). Serine 111 appears to facilitate phosphorylation at
S112 because mutating it reduces phosphorylation by Pak1, but
not PKA (Figure 4). Raf-1 is widely studied for its role in cell
proliferation through phosphorylation of MEK and ERK.
Increasingly, MEK independent signals have been identified to
promote cell survival. The MEK independent survival signals play
a major role in the physiology of B-Raf and Raf-1. Cells from
knockouts of both B-Raf and Raf-1 display normal proliferative
rates but increased rates of apoptosis [14,40–44] while knockouts
of MEK1 display no increases in apoptosis [45]. Cells from Raf-1
knockouts also have wild type levels of ERK activation, suggesting
that the survival signals are independent of MEK and ERK. Our
data suggest Pak1 and Raf-1 cooperate to maintain BAD
phosphorylation at S112 but not at S111, and that MEK signaling
is not involved in phosphorylation at either site.
An unexpected observation from this study is that there is a
difference in the sensitivity of downstream pathways to Raf
inhibitors. We found that a Raf-1 inhibitor reduced phosphory-
lation of BAD at S112 in 293T cells under a condition where it
actually slightly increased phosphorylation of Erk1 (Figure 3A,
lane 4). This difference may be caused by different isoforms of Raf
signaling to the two pathways. For example, in some cells, B-Raf
may be the primary kinase for the ERK pathway while Raf-1 may
be the primary kinase for BAD. It was recently shown that low
doses Raf inhibitors stimulated ERK in cells that harbor wild-type
Raf and/or activated Ras. This is because inactivated B-Raf forms
heterodimers with Raf-1, which then becomes activated to
stimulate ERK [46–49]. Our studies raise the possibility that
Raf inhibitor-activated Rafs may be unable to phosphorylate BAD
at S112.
The role of Raf in cell survival pathways may explain why Raf
inhibitors are performing better in the clinic than MEK inhibitors
[46]. Since MEK inhibitors do not prevent BAD phosphorylation,
they only partially disrupt Raf signaling. We speculate that
blocking the survival signals may be required for clinical responses
to Raf inhibitors. The survival signals appear to be especially
important for liver cells since liver carcinomas respond well to Raf
inhibitors, such as Sorafenib, and Raf-1 knockout mice have high
rates of liver apoptosis [14,42]. Our studies support the expanding
role of Pak1 in cell survival signals through Raf-1 regulation of
BAD phosphorylation and suggest that Pak1 inhibitors may
enhance the effectiveness of MEK inhibitors by reducing MEK-
independent signals from Raf (Figure 6C). The observation of
BAD S111 phosphorylation in a lung cancer cell line and several
Figure 6. Pak1 inhibition reduced BAD S111 and S112
phosphorylation. (A) BAD S111 phosphorylation was observed in a
lung cancer cell line H358 and the MPNST cell lines 90-8 and STS26. (B)
Effects of protein kinase inhibitors on BAD S111 and S112 phosphor-
ylation. The MPNST cells, ST88-14, were starved and treated with vehicle
(DMSO), IPA3 (20 mM), GW5074 (5 mM), or H89 (5 mM) for 15 hr. Equal
amounts of proteins were used for Western blot to assess BAD
phosphorylation at S111and S112. The cell lysates were also subjected
to immunoblotting with anti-BAD. As a control, Raf-1 phosphorylation
at S338 was examined. (C) Model showing that Pak1 phosphorylates
BAD at S111 directly, but most of its protective effects are mediated
through Raf-1 and phosphorylation of S112. S111 also appears to
facilitate phosphorylation at S112 because mutating it reduces
phosphorylation by Pak1, but not phosphorylation by PKA. S136 is
the most important phosphorylation site for the BAD/14-3-3 complex
formation as previously observed. The enhanced Bcl-2 binding by the
triple mutant is likely the result of the release of BAD from 14-3-3
sequestering in addition to the enhanced Bcl-2 association.
doi:10.1371/journal.pone.0027637.g006
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used as pharmacodynamic marker of Pak activity in some cancers.
Supporting Information
Figure S1 In vitro protein and peptide kinase assays. (A)
Coomassie brilliant blue staining of the gel of Figure 1C. (B)
Coomassie brilliant blue staining of the gel of Figure 1D. (C)
Coomassie brilliant blue staining of the purified proteins. All
proteins were purified from E. coli through glutathione sephorase
4B columns except His-Pak1 which was purified from sf 9 insect
cells through a Ni-NTA agarose column. Wild type (WT) and
mutant GST-BAD fusion proteins contain a murine BAD
fragment (aa 104-141). 2 mg of His-Pak1, 1mg of GST-Cdc42
L61,
2 mg of GST and 6 mg of GST-BAD proteins were applied to 10%
SDS-PAGE and stained with Coomassie Brilliant Blue. (D)
Purified BAD peptides (aa 105-118) were incubated with Rac
L61,
Pak1 or both with c
32P-ATP and subjected to autoradiography.
(TIF)
Figure S2 (A) Purified GST-BAD was incubated with or without
PKA and phosphorylated with c
32P-ATP ATP (upper panel) and
subjected to autoradiography, or phosphorylated with unlabeled
ATP (lower two panels) and probed with the S111 and S112
antibodies. (B) Purified BAD peptides (aa 105-118) were incubated
with activated Raf-1, Pak1 or both with c
32P-ATP ATP, run on a
tricine gel and subjected to autoradiography. Bottom panel of B
shows phosphorimager quantification of the bands in panel D
(n=2). Student t-test was performed and * p,0.05. The arrows
indicate the bands that were quantified.
(TIF)
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